Axogen, Inc. Reports First Quarter 2026 Financial Results

ALACHUA, Fla. and TAMPA, Fla., April 28, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the first quarter ended March 31, 2026.

First Quarter Financial Results 

• First quarter 2026 revenue was $61.5 million, a 26.6% increase compared to first quarter 2025 revenue of $48.6 million.

• Gross margin was 75.2% for the first quarter of 2026, compared to 71.9% in the first quarter of 2025.

• Net loss for the first quarter of 2026 was $19.6 million, or $0.38 per share, compared to $3.8 million, or $0.08 per share for the first quarter of 2025.

• Adjusted net income was $4.1 million for the first quarter of 2026, or $0.07 per share, compared to an adjusted net loss of $0.9 million, or $0.02 per share for the first quarter 2025.

• Adjusted EBITDA was $5.7 million for the first quarter of 2026, compared to $2.9 million for the first quarter of 2025.

• As of March 31, 2026, cash and cash equivalents, restricted cash, and investments was $103.6 million, as compared to $45.5 million as of December 31, 2025, an increase of $58.1 million.
  
  
  
  

"We are pleased with our first-quarter revenue performance and the progress we're making across each of Axogen's strategic plan priorities," said Michael Dale, President and CEO of Axogen, Inc. "We delivered strong growth across all of our target markets, reinforcing the relevance of our market development strategies and the strength of our commercial execution. We remain well positioned to achieve our financial guidance and continue advancing our strategic objectives for 2026."

Summary of Business Highlights

• First quarter 2026 revenue growth was broad-based, including double-digit growth in all markets, which includes Extremities, Oral Maxillofacial & Head and Neck, and Breast.

• Received positive coverage decisions from Cigna and Elevance Health, two of the nation's largest commercial insurers.

• Effective January 1, 2026, CMS created a new Level 3 Nerve Procedure Code, increasing Avance facility reimbursement 40% year-over-year to $8,965 for hospital outpatient and 35% to $6,157 for ASC-based procedures.

• On January 23, 2026, Axogen closed an upsized public offering with the sale of 4.6 million shares of common stock, yielding net proceeds of $133.3 million. From these net proceeds, $69.7 million were used to fully repay and terminate our Oberland loan facility on January 28, 2026. Remaining funds are available for working capital, capital expenditures, and other general corporate purposes.
  
  
  
  

2026 Financial Guidance

We expect 2026 revenue growth to be at least 20%, or $270 million, for the full-year and gross margin to be in the range of 74% to 76%. Additionally, we expect to be free cash flow positive for the full-year.

Conference Call

The Company will host a conference call and webcast for the investment community today at 8:00 a.m. ET. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the Company's website at www.axogeninc.com and clicking on the webcast link.

Following the conference call, a replay will be available in the Investors section of the Company's website at www.axogeninc.com under Investors.

About Axogen

Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.

Axogen's product portfolio includes Avance^® (acellular nerve allograft-arwx), Avance^® Nerve Graft, Axoguard Nerve Connector^®, Axoguard Nerve Protector^®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap^®, and Avive+ Soft Tissue Matrix™.​

For more information, visit www.axogeninc.com.

Cautionary Statements Concerning Forward-Looking Statements

This press release and accompanying earnings call contain "forward-looking" statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements under the heading "2026 Financial Guidance" and statements regarding our business model optimization plans; market development strategies and objectives; our expectations around the potential positive impact on our business of expanded coverage and reimbursement for peripheral nerve injuries using synthetic conduits or allografts; our ability to sustain growth, operate profitably, generate positive cash flows, and fund our market development initiatives; and the anticipated use of proceeds from our recent public offering. These statements are based on management's current expectations and estimates of trends and economic factors in the markets in which we are active. Words such as "expects," "anticipates," "objectives," "targets," "intends," "plans," "believes," "seeks," "estimates," "projects," "forecasts," "continue," "may," "should," "will," and variations of such words and similar expressions are intended to identify such forward-looking statements. Actual results or events could differ materially from those described in any forward-looking statements as a result of factors, including, without limitation, disruptions from global supply chain issues, inflation, hospital staffing challenges, product development timelines, regulatory processes, financial performance, surgeon adoption rates, market awareness of our products, the estimated total addressable market, as well as those risk factors described under Part I, Item 1A, "Risk Factors," in our most recent Annual Report on Form 10-K and other risks and uncertainties that may be detailed from time to time in reports filed by the Company with the SEC. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. Forward-looking statements speak only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements.

About Non-GAAP Financial Measures

To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, EBITDA margin, and Adjusted EBITDA, which further excludes non-cash stock-based compensation expense and the loss on extinguishment of debt, and Adjusted EBITDA margin. We also use the non-GAAP financial measures of Adjusted Net Income (Loss) and Adjusted Net Income (Loss) Per Common Share - diluted which excludes non-cash stock-based compensation expense and the loss on extinguishment of debt from Net Loss and Net Loss Per Common Share - diluted. Additionally, we use the non-GAAP financial measure of Free Cash Flow which consists of net cash provided by operating activities, less expenditures for property and equipment, and intangible assets.

These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated.

We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (i) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (ii) they are used by our institutional investors and the analyst community to help them analyze the performance of our business.

Contact: Axogen, Inc. InvestorRelations@axogeninc.com

Axogen, Inc. Condensed Consolidated Balance Sheets (unaudited) (in thousands, except share and per share amounts)
​		March 31, 2026				December 31, 2025
Assets						​
Current assets:
Cash and cash equivalents		$	82,654			$	35,548
Restricted cash			2,000				4,000
Investments			18,947				5,980
Accounts receivable, net of allowance for doubtful accounts of $822 and $948, respectively			28,313				26,169
Inventory			46,074				42,373
Prepaid expenses and other assets			6,720				6,352
Total current assets			184,708				120,422
Property and equipment, net			83,038				81,783
Operating lease right-of-use assets			14,280				12,732
Intangible assets, net			7,270				6,750
Other assets			192				—
Total assets		$	289,488			$	221,687
​
Liabilities and shareholders' equity
Current liabilities:
Accounts payable and accrued expenses		$	23,898			$	21,184
Current maturities of long-term lease obligations			2,115				2,372
Total current liabilities			26,013				23,556
​
Long-term debt, net of debt discount and financing fees			—				48,387
Long-term lease obligations			18,527				16,870
Debt derivative liabilities			—				3,886
Other long-term liabilities			140				141
Total liabilities			44,680				92,840
​
Shareholders' equity:
Common stock, $0.01 par value per share; 100,000,000 shares authorized; 53,153,471 and 47,199,797 shares issued and outstanding, respectively			532				472
Additional paid-in capital			570,823				435,338
Accumulated deficit			(326,547	)			(306,963	)
Total shareholders' equity			244,808				128,847
Total liabilities and shareholders' equity		$	289,488			$	221,687

​

Axogen, Inc. Condensed Consolidated Statements of Operations (unaudited) (in thousands, except share and per share amounts)
​		Three Months Ended
​		March 31, 2026				March 31, 2025
Revenues		$	61,457			$	48,560
Cost of goods sold			15,268				13,627
Gross profit			46,189				34,933
Costs and expenses:
Sales and marketing			28,633				21,045
Research and development			7,517				6,091
General and administrative			12,871				9,458
Total costs and expenses			49,021				36,594
Loss from operations			(2,832	)			(1,661	)
Other income (expense):
Investment income			768				272
Interest expense			(694	)			(2,250	)
Loss on extinguishment of debt			(16,849	)			—
Change in fair value of debt derivative liabilities			—				(158	)
Other income (expense), net			23				(37	)
Total other expense, net			(16,752	)			(2,173	)
Net loss		$	(19,584	)		$	(3,834	)
Weighted average common shares outstanding — basic			51,591,504				45,204,076
Weighted average common shares outstanding — diluted			51,591,504				45,204,076
Net loss per common share — basic		$	(0.38	)		$	(0.08	)
Net loss per common share — diluted		$	(0.38	)		$	(0.08	)

Axogen, Inc. Condensed Consolidated Statements of Cash Flows (unaudited) (in thousands)​
​		Three Months Ended
​		March 31, 2026				March 31, 2025
Cash flows from operating activities:		​
Net loss		$	(19,584	)		$	(3,834	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation			1,604				1,728
Amortization of right-of-use assets			420				87
Amortization of intangible assets			101				67
Amortization of debt discount and deferred financing fees			68				220
(Recovery of) provision for bad debts			(120	)			187
Change in fair value of debt derivative liabilities			—				158
Investment losses (gains), net			33				(45	)
Loss on extinguishment of debt			16,849				—
Stock-based compensation expense			6,843				2,909
Change in operating assets and liabilities:
Accounts receivable			(2,024	)			(2,377	)
Inventory			(3,701	)			(2,321	)
Prepaid expenses and other assets			(368	)			(489	)
Other assets			(192	)			—
Accounts payable and accrued expenses			2,198				(9,079	)
Operating lease obligations			(559	)			(452	)
Cash paid for interest portion of financing lease obligations			(2	)			(1	)
Other long-term liabilities			(1	)			63
Net cash provided by (used in) operating activities			1,565				(13,179	)
​		​
Cash flows from investing activities:		​
Purchase of property and equipment			(2,789	)			(256	)
Purchase of investments			(19,000	)			—
Proceeds from sale of investments			6,000				2,000
Cash payments for intangible assets			(175	)			(405	)
Net cash (used in) provided by investing activities			(15,964	)			1,339
​		​
Cash flows from financing activities:		​
Proceeds from issuance of common stock			134,044				—
Payment of stock issuance costs			(792	)			—
Repayment of long-term debt			(48,585	)			—
Fees paid to lender related to debt extinguishment			(20,498	)			—
Fees paid to third parties related to debt extinguishment			(107	)			—
Payments of employee tax withholding on vested stock awards			(8,776	)			—
Cash paid for debt portion of financing lease obligations			(7	)			(1	)
Proceeds from exercise of stock options			4,226				2,383
Net cash provided by financing activities			59,505				2,382
Net increase (decrease) in cash and cash equivalents, and restricted cash			45,106				(9,458	)
Cash and cash equivalents, and restricted cash, beginning of period			39,548				33,554
Cash and cash equivalents, and restricted cash, end of period		$	84,654			$	24,096

Axogen, Inc. Condensed Consolidated Statements of Changes in Shareholders' Equity (unaudited) (in thousands, except share amounts)
​		Common Stock							Additional Paid-in Capital				Accumulated Deficit				Total Shareholders' Equity
​		Shares			Amount
Three Months Ended March 31, 2026		​			​				​				​				​
Balance at December 31, 2025		47,199,797			$	472			$	435,338			$	(306,963	)		$	128,847
Net loss		—				—				—				(19,584	)			(19,584	)
Issuance of common shares		4,600,000				46				133,206				—				133,252
Stock-based compensation		—				—				6,843				—				6,843
Issuance of restricted and performance stock units, net of shares withheld for withholding taxes		985,796				10				(8,786	)			—				(8,776	)
Exercise of stock options		367,878				4				4,222				—				4,226
Balance at March 31, 2026		53,153,471			$	532			$	570,823			$	(326,547	)		$	244,808
Three Months Ended March 31, 2025
Balance at December 31, 2024		44,148,836			$	441			$	394,726			$	(291,260	)		$	103,907
Net loss		—				—				—				(3,834	)			(3,834	)
Stock-based compensation		—				—				2,909				—				2,909
Issuance of restricted and performance stock units		1,105,214				11				(11	)			—				—
Exercise of stock options		258,573				3				2,380				—				2,383
Balance at March 31, 2025		45,512,623			$	455			$	400,004			$	(295,094	)		$	105,365

Axogen, Inc. Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (unaudited) (in thousands, except share and per share amounts)​
EBITDA & Adjusted EBITDA		Three Months Ended
		March 31, 2026				March 31, 2025
Net loss		$	(19,584	)		$	(3,834	)
Depreciation and amortization expense			1,706				1,795
Investment income			(768	)			(272	)
Income tax (benefit) expense			(33	)			29
Interest expense			694				2,250
EBITDA – non-GAAP		$	(17,985	)		$	(32	)
EBITDA margin – non-GAAP			(29.3	)%			(0.1	)%
Non-cash stock-based compensation expense			6,843				2,909
Loss on extinguishment of debt			16,849				—
Adjusted EBITDA – non-GAAP		$	5,707			$	2,877
Adjusted EBITDA margin – non-GAAP			9.3	%			5.9	%

​

Axogen, Inc. Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (unaudited) (in thousands, except share and per share amounts)​
Adjusted Net Income		Three Months Ended March 31, 2026
		GAAP Results				Non-cash Stock-based Compensation Expense				Loss on Extinguishment of Debt				Dilutive Shares Impact(1)				Adjusted Results
Revenues		$	61,457			$	—			$	—							$	61,457
Cost of goods sold			15,268				(919	)			—								14,349
Gross profit			46,189				919				—								47,108
Costs and expenses:
Sales and marketing			28,633				(1,558	)			—								27,075
Research and development			7,517				(1,419	)			—								6,098
General and administrative			12,871				(2,947	)			—								9,924
Total costs and expenses			49,021				(5,924	)			—								43,097
(Loss) income from operations			(2,832	)			6,843				—								4,011
Other income (expense):
Investment income			768				—				—								768
Interest expense			(694	)			—				—								(694	)
Loss on extinguishment of debt			(16,849	)			—				16,849								—
Other income, net			23				—				—								23
Total other (expense) income, net			(16,752	)			—				16,849								97
Net (loss) income		$	(19,584	)		$	6,843			$	16,849							$	4,108
Weighted average common shares outstanding – diluted			51,591,504				51,591,504				51,591,504				5,183,717				56,775,221
Net (loss) income per common share – diluted		$	(0.38	)		$	0.13			$	0.33			$	(0.01	)		$	0.07
__________ (1) Due to a GAAP net loss, antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding. However, considering the adjusted net income position, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP.

Axogen, Inc. Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (unaudited) (in thousands, except share and per share amounts)​
Adjusted Net Income		Three Months Ended March 31, 2025												Three Months Ended June 30, 2025												Three Months Ended September 30, 2025												Three Months Ended December 31, 2025
		GAAP Results				Non-cash Stock-based Compensation Expense				Adjusted Results				GAAP Results				Non-cash Stock-based Compensation Expense				Adjusted Results				GAAP Results				Non-cash Stock-based Compensation Expense				Adjusted Results				GAAP Results				Non-cash Stock-based Compensation Expense				Adjusted Results(1)
Revenues		$	48,560			$	—			$	48,560			$	56,662			$	—			$	56,662			$	60,082			$	—			$	60,082			$	59,904			$	—			$	59,904
Cost of goods sold			13,627				10				13,637				14,644				(709	)			13,935				14,089				(706	)			13,383				15,495				(2,274	)			13,221
Gross profit			34,933				(10	)			34,923				42,018				709				42,727				45,993				706				46,699				44,409				2,274				46,683
Costs and expenses:
Sales and marketing			21,045				(584	)			20,461				23,804				(1,314	)			22,490				25,680				(1,524	)			24,156				27,211				(2,939	)			24,272
Research and development			6,091				(720	)			5,371				6,853				(1,030	)			5,823				7,565				(1,047	)			6,518				12,376				(6,052	)			6,324
General and administrative			9,458				(1,615	)			7,843				9,689				(2,115	)			7,574				10,836				(2,147	)			8,689				14,594				(5,346	)			9,248
Total costs and expenses			36,594				(2,919	)			33,675				40,346				(4,459	)			35,887				44,081				(4,718	)			39,363				54,181				(14,337	)			39,844
(Loss) income from operations			(1,661	)			2,909				1,248				1,672				5,168				6,840				1,912				5,424				7,336				(9,772	)			16,611				6,839
Other income (expense):
Investment income			272				—				272				225				—				225				319				—				319				352				—				352
Interest expense			(2,250	)			—				(2,250	)			(1,977	)			—				(1,977	)			(1,757	)			—				(1,757	)			(1,718	)			—				(1,718	)
Change in fair value of debt derivative liabilities			(158	)			—				(158	)			480				—				480				209				—				209				(2,018	)			—				(2,018	)
Other (expense) income, net			(37	)			—				(37	)			179				—				179				25				—				25				—				—				—
Total other expense, net			(2,173	)			—				(2,173	)			(1,093	)			—				(1,093	)			(1,204	)			—				(1,204	)			(3,384	)			—				(3,384	)
Net (loss) income		$	(3,834	)		$	2,909			$	(925	)		$	579			$	5,168			$	5,747			$	708			$	5,424			$	6,132			$	(13,156	)		$	16,611			$	3,455
Weighted average common shares outstanding – diluted			45,204,076				45,204,076				45,204,076				47,980,830				47,980,830				47,980,830				49,088,436				49,088,436				49,088,436				46,929,309				46,929,309				52,230,508
Net (loss) income per common share – diluted		$	(0.08	)		$	0.06			$	(0.02	)		$	0.01			$	0.11			$	0.12			$	0.01			$	0.11			$	0.12			$	(0.28	)		$	0.35			$	0.07
__________ (1) Due to a GAAP net loss during the three months ended December 31, 2025, 5,301,199 antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding. However, considering the adjusted net income position, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP. The inclusion of these shares decreased adjusted Net income per common share by less than $0.01.

Axogen, Inc. Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures (unaudited) (in thousands, except share and per share amounts)​
Adjusted Net Income		Twelve Months Ended December 31, 2025
		GAAP Results				Non-cash Stock-based Compensation Expense				Dilutive Shares Impact(1)				Adjusted Results
Revenues		$	225,208			$	—							$	225,208
Cost of goods sold			57,855				(3,680	)							54,175
Gross profit			167,353				3,680								171,033
Costs and expenses:
Sales and marketing			97,740				(6,361	)							91,379
Research and development			32,885				(8,848	)							24,037
General and administrative			44,577				(11,223	)							33,354
Total costs and expenses			175,202				(26,432	)							148,770
(Loss) income from operations			(7,849	)			30,112								22,263
Other income (expense):
Investment income			1,168				—								1,168
Interest expense			(7,702	)			—								(7,702	)
Change in fair value of debt derivative liabilities			(1,487	)			—								(1,487	)
Other income, net			167				—								167
Total other expense, net			(7,854	)			—								(7,854	)
Net (loss) income		$	(15,703	)		$	30,112							$	14,409
Weighted average common shares outstanding – diluted			46,050,266				46,050,266				3,761,920				49,812,186
Net (loss) income per common share – diluted		$	(0.34	)		$	0.65			$	(0.02	)		$	0.29
__________ (1) Due to a GAAP net loss, antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding. However, considering the adjusted net income position, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP.

Free Cash Flow		Three Months Ended
		March 31, 2026				March 31, 2025
Net cash provided by (used in) operating activities		$	1,565			$	(13,179	)
Purchase of property and equipment			(2,789	)			(256	)
Cash payments for intangible assets			(175	)			(405	)
Free cash flow		$	(1,399	)		$	(13,840	)